Natco Pharma has announced final approval of the Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration for Bosentan tablets in 62.5 mg and 125 mg strengths. Bosentan is used for treatment of patients with pulmonary arterial hypertension. Natco’s tablets are marketed by its partner Lupin. As per IQVIA MAT March 2019 data, Bosentan tablets 62.5 mg and 125 mg had annual sales of around $84.8 million in the US market. Shares of Natco Pharma closed 1.94 per cent lower at ₹533.60 while those of Lupin gained 0.47 per cent at ₹874.80 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.